HK1139006A1 - Methods for treating neoplasia with combination of chemotherapeutic agents and radiation - Google Patents

Methods for treating neoplasia with combination of chemotherapeutic agents and radiation

Info

Publication number
HK1139006A1
HK1139006A1 HK10105832.9A HK10105832A HK1139006A1 HK 1139006 A1 HK1139006 A1 HK 1139006A1 HK 10105832 A HK10105832 A HK 10105832A HK 1139006 A1 HK1139006 A1 HK 1139006A1
Authority
HK
Hong Kong
Prior art keywords
radiation
methods
combination
sub
chemotherapeutic agents
Prior art date
Application number
HK10105832.9A
Other languages
English (en)
Inventor
Bo Xu
Original Assignee
Southern Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Southern Res Inst filed Critical Southern Res Inst
Publication of HK1139006A1 publication Critical patent/HK1139006A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK10105832.9A 2007-04-14 2010-06-11 Methods for treating neoplasia with combination of chemotherapeutic agents and radiation HK1139006A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91187407P 2007-04-14 2007-04-14
PCT/US2008/060214 WO2008128170A1 (en) 2007-04-14 2008-04-14 Methods for treating neoplasia with combination of chemotherapeutic agents and radiation

Publications (1)

Publication Number Publication Date
HK1139006A1 true HK1139006A1 (en) 2010-09-10

Family

ID=39864369

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10105832.9A HK1139006A1 (en) 2007-04-14 2010-06-11 Methods for treating neoplasia with combination of chemotherapeutic agents and radiation

Country Status (16)

Country Link
US (1) US9757380B2 (ja)
EP (1) EP2136631B1 (ja)
JP (1) JP5337143B2 (ja)
KR (1) KR101449579B1 (ja)
CN (1) CN101686673B (ja)
AU (1) AU2008240118B2 (ja)
BR (1) BRPI0809937A2 (ja)
CA (1) CA2683637C (ja)
EA (1) EA017753B1 (ja)
ES (1) ES2390801T3 (ja)
HK (1) HK1139006A1 (ja)
MX (1) MX2009011104A (ja)
NZ (1) NZ580463A (ja)
PT (1) PT2136631E (ja)
WO (1) WO2008128170A1 (ja)
ZA (1) ZA200907072B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090082437A1 (en) * 2007-09-26 2009-03-26 Mackay Memorial Hospital Use of Oxaliplatin for Enhancing Radiosensitivity in Radiotherapy of Cervical Cancer
WO2017155082A1 (ja) * 2016-03-11 2017-09-14 国立大学法人鹿児島大学 抗肝腫瘍ウイルス剤
US11202792B2 (en) 2016-10-12 2021-12-21 Georgetown University CD99 inhibitors and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585363A (en) * 1987-05-05 1996-12-17 City Of Hope Circumvention of human tumor drug resistance
US5384310A (en) 1989-05-23 1995-01-24 Southern Research Institute 2'-fluoro-2-haloarabinoadinosines and their pharmaceutical compositions
CA2045601A1 (en) * 1989-12-08 1991-06-09 Kevin J. Scanlon Circumvention of human tumor drug resistance
US20030229004A1 (en) * 2002-03-20 2003-12-11 Pangene Corporation Modulation of tumor cells using BER inhibitors in combination with a sensitizing agent and DSBR inhibitors
EP1804816B1 (en) 2004-03-26 2011-12-21 Vion Pharmaceuticals, Inc. Combination therapy comprising cloretazine(tm)
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
JP2008516938A (ja) * 2004-10-15 2008-05-22 アストラゼネカ アクチボラグ 置換アデニンとその使用
MX2007005474A (es) 2004-11-08 2007-07-10 Transgene Sa Equipo de partes disenado para implementar un tratamiento antitumoral o antiviral en un mamifero.
CN100569289C (zh) 2006-07-18 2009-12-16 济南康泉医药科技有限公司 同载铂类化合物和克罗拉滨的抗癌药物组合物

Also Published As

Publication number Publication date
CA2683637A1 (en) 2008-10-23
JP5337143B2 (ja) 2013-11-06
CN101686673B (zh) 2013-06-12
AU2008240118B2 (en) 2014-02-13
US20080262003A1 (en) 2008-10-23
BRPI0809937A2 (pt) 2014-09-23
WO2008128170A1 (en) 2008-10-23
AU2008240118A1 (en) 2008-10-23
KR101449579B1 (ko) 2014-10-13
US9757380B2 (en) 2017-09-12
CN101686673A (zh) 2010-03-31
EP2136631A1 (en) 2009-12-30
EP2136631B1 (en) 2012-08-15
ES2390801T3 (es) 2012-11-16
MX2009011104A (es) 2010-01-18
NZ580463A (en) 2011-03-31
ZA200907072B (en) 2010-06-30
PT2136631E (pt) 2012-09-27
EP2136631A4 (en) 2010-08-04
EA017753B1 (ru) 2013-02-28
EA200970949A1 (ru) 2010-04-30
JP2010523721A (ja) 2010-07-15
KR20090130131A (ko) 2009-12-17
CA2683637C (en) 2013-02-19

Similar Documents

Publication Publication Date Title
MX2012001654A (es) Metodos para usar moduladores de c-met.
TW200730532A (en) Camptothecin derivatives as chemoradiosensitizing agents
HK1139863A1 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha
PT2139483E (pt) Terapias de combinação que compreendem um inibidor de quinoxalina de pi3k-alfa para utilizar no tratamento de cancro
TW200718689A (en) 2-Amino-quinazolin-5-ones
TW200738262A (en) Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP1622608A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
GEP20125469B (en) Inhibitors of akt activity
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
MY183661A (en) Treatment of cancer with tor kinase inhibitors
MX2011008221A (es) Tratamiento de cancer de pulmon con un compuesto de nitrobenzamida en combinacion con un inhibidor de un factor de crecimieno.
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
UY28081A1 (es) Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular
MX2009012708A (es) Derivados de piridazinona.
GB0802753D0 (en) Perylenequinone derivatives and uses thereof
MX2009008549A (es) Tratamiento de canceres resistentes o refractarios con conjugados polimericos de brazos multiples de 7-etil-10-hidroxicamptotecina.
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
TNSN07294A1 (en) Treatment of metastasized tumors
MX2009006574A (es) Tratamiento de cancer de pulmon.
SG171674A1 (en) Methods of treating cancer by administering human il-18 combinations
GB0416508D0 (en) Therapeutic agents
HK1139006A1 (en) Methods for treating neoplasia with combination of chemotherapeutic agents and radiation
NO20053339L (no) Levalbuterolsalt.
MY155342A (en) Antitumoral compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190414